J&J’s Spravato Approved for Standalone Use in Severe Depression Treatment
The US Food and Drug Administration (FDA) has expanded approval for Johnson & Johnson’s Spravato, a nasal spray derived from ketamine, to allow its standalone use as a treatment for patients with severe depression. The company announced the news on Tuesday. Spravato was initially approved in 2019 as an adjunct therapy for depressive episodes and … Read more